Subjects n | 25 | 25 |
Age yrs | 11.0 (9.3–12.4) | 11.2 (8.4–13) |
Males | 18 (72) | 19 (76) |
Duration of asthma yrs | 6.0 (3.3–8.3) | 4.3 (3.2–5.2) |
≥2 hospitalisations for asthma during the past year | 7 (28) | 5 (20) |
Ever ICU admission | 4 (16) | 2 (8) |
Pre-β2-agonist FEV1 % pred | 87.4 (79.9–103.0) | 83.3 (72.4–96.2) |
Pre-β2-agonist FEF25–75% % pred | 53.6 (41.1–73.7) | 51.3 (37.5–68.9) |
Post-β2-agonist FEV1 % pred | 110 (101–112) | 103 (95–108) |
Post-β2-agonist FEF25–75% % pred | 84 (69–95) | 81 (66–100) |
ICS dose μg equivalent BUD·day−1 | 1000 (800–1200) | 1200 (800–2000) |
PAQLQ overall score | 4.2 (3.7–4.8) | 4.2 (3.4–5.3) |
PAQLQ domains | | |
Symptoms | 3.8 (3.4–4.7) | 4.0 (3.1–5.0) |
Activities | 3.6 (3.2–4.2) | 4.0 (2.6–4.8) |
Emotions | 4.9 (4.2–6.1) | 5.1 (3.9–6.4) |
Other allergic features | | |
Rhinitis | 10 (40) | 11 (44) |
Eczema | 14 (58) | 7 (28) |
Food allergy | 5 (21) | 3 (12.5) |